Amoéba
Develops natural microbiological solutions to manage bacterial and fungal risks.
ALMIB | PA
Overview
Corporate Details
- ISIN(s):
- FR0011051598 (+2 more)
- LEI:
- 9695005QNE7C8Z0LXU64
- Country:
- France
- Address:
- 38 AVENUE DES FRERES MONTGOLFIER, 69680 CHASSIEU
- Website:
- https://amoeba-nature.com/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of other chemical products
Description
Amoéba is a biotechnology company that develops natural microbiological solutions for managing bacterial and fungal risks. The company's core technology is based on the patented use of the amoeba *Willaertia magna* C2c Maky and its biocidal properties. Its primary focus is on agricultural biocontrol, offering a biofungicide derived from a mechanically lysed amoeba. This product targets plant diseases such as mildews, rusts, and powdery mildew, providing a biological alternative to chemical treatments. Amoéba has also developed applications for its technology in the treatment of bacterial risk in industrial water systems, on surfaces, and for chronic wounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2018-04-05 17:40 |
AMOEBA CONFIRME LES ETAPES REGLEMENTAIRES EUROPEENNES
|
French | PDF • 148.5 KB | ||
| 2018-04-05 17:40 |
AMOEBA CONFIRMS THE EUROPEAN REGULATORY STAGES
|
English | PDF • 139.3 KB | ||
| 2018-03-23 17:45 |
CP Amoeba : Résultats annuels 2017 conformes au plan de développement
|
French | PDF • 214.3 KB | ||
| 2018-03-23 17:45 |
2017 full-year results in line with development plan
|
English | PDF • 207.1 KB | ||
| 2018-02-02 11:29 |
Franchissement de seuils
|
French | PDF • 21.2 KB | ||
| 2018-01-23 17:40 |
AMOEBA INFORME DE LA TENUE DU SECOND GROUPE DE TRAVAIL EUROPEEN SUR SON DOSSIER…
|
French | PDF • 392.1 KB | ||
| 2018-01-03 17:10 |
AMOEBA : Bilan semestriel du contrat de liquidité
|
French | PDF • 396.8 KB | ||
| 2018-01-03 17:10 |
AMOEBA : Half-year review of the liquidity contract
|
English | PDF • 394.7 KB | ||
| 2017-11-22 18:00 |
AMOEBA and CONIDIA validate the effect of Willaertia Magna as a biocontrol agen…
|
English | PDF • 412.0 KB | ||
| 2017-11-22 18:00 |
AMOEBA et CONIDIA valident l’effet de Willaertia Magna comme agent de biocontrô…
|
French | PDF • 420.5 KB | ||
| 2017-11-08 17:45 |
Amoeba signe une Lettre d’Intention avec H2O FACILITIES.
|
French | PDF • 408.5 KB | ||
| 2017-11-08 17:45 |
Amoeba signs a Letter of Intent with H2O FACILITIES.
|
English | PDF • 395.8 KB | ||
| 2017-10-06 17:40 |
La Banque européenne d’investissement (BEI) accorde une ligne de financement de…
|
French | PDF • 443.1 KB | ||
| 2017-10-06 17:40 |
European Investment Bank (EIB) provides EUR 20m credit line to Amoéba to revolu…
|
English | PDF • 304.3 KB | ||
| 2017-09-29 17:40 |
AMOEBA INFORME DE LA DATE DEFINITIVE DE L’OPINION DU COMITE DES PRODUITS BIOCID…
|
French | PDF • 650.1 KB |
Automate Your Workflow. Get a real-time feed of all Amoéba filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Amoéba
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Amoéba via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-08-30 | N/A | Other | Buy | 6,300 | 3,609.90 EUR |
| 2024-08-29 | N/A | Other | Sell | 5,500 | 3,564.00 EUR |
| 2024-08-28 | N/A | Other | Buy | 3,200 | 1,782.08 EUR |
| 2024-08-27 | N/A | Other | Buy | 20,049 | 11,231.45 EUR |
| 2024-08-26 | N/A | Other | Buy | 31,107 | 17,441.69 EUR |
| 2024-08-22 | N/A | Other | Buy | 2,255 | 1,298.88 EUR |
| 2024-08-20 | N/A | Other | Buy | 16,664 | 8,838.59 EUR |
| 2024-08-19 | N/A | Other | Buy | 13,390 | 6,795.43 EUR |
| 2024-08-16 | N/A | Other | Buy | 6,745 | 3,468.28 EUR |
| 2024-08-09 | N/A | Other | Buy | 40,748 | 21,559.77 EUR |
Peer Companies
